Protein tyrosine phosphatase inhibitors and methods of use...

Details Protein tyrosine phosphatase inhibitors and methods of use... Protein tyrosine phosphatase inhibitors and methods of use...

2008-03-06

2010-11-09

Shiao, Rei-tsang (Department: 1628)

Organic compounds -- part of the class 532-570 series

Organic compounds

Phosphorus esters

C558S089000

Reexamination Certificate

active

07829737

ABSTRACT:
The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases.

REFERENCES:
patent: 4668506 (1987-05-01), Bawa
patent: 4713244 (1987-12-01), Bawa
patent: 4816570 (1989-03-01), Farquhar
patent: 4931279 (1990-06-01), Bawa
patent: 4968788 (1990-11-01), Farquhar
patent: 5411947 (1995-05-01), Hostetler
patent: 5463092 (1995-10-01), Hostetler
patent: 6312662 (2001-11-01), Erion
patent: 6348572 (2002-02-01), Desmarais
patent: 6498151 (2002-12-01), Li et al.
patent: 6583126 (2003-06-01), Leblanc et al.
patent: 6716825 (2004-04-01), Hostetler
patent: 6752981 (2004-06-01), Erion
patent: 6903081 (2005-06-01), Borch
patent: 2002/0004594 (2002-01-01), Borch
patent: 2003/0225277 (2003-12-01), Kopcho
patent: 2003/0229225 (2003-12-01), Reddy
patent: 2004/0176330 (2004-09-01), Dufresne et al.
patent: 2005/0171060 (2005-08-01), Borch
patent: WO 90/00555 (1990-01-01), None
patent: WO 94/08600 (1994-04-01), None
patent: WO 96/39831 (1996-12-01), None
patent: WO 98/20024 (1998-05-01), None
patent: WO 98/20156 (1998-05-01), None
patent: WO 99/46268 (1999-09-01), None
patent: WO 99/47529 (1999-09-01), None
patent: WO 00/17211 (2000-03-01), None
patent: WO 00/69889 (2000-11-01), None
patent: WO 01/18013 (2001-03-01), None
patent: WO 03/041729 (2003-05-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 03/095665 (2003-11-01), None
patent: WO 2004/079012 (2004-09-01), None
Andersen et al., “Structural and evolutionary relationships among Protein Tyrosine Phosphatase domains”Mol. Cell Biol. 21:7117-36 (2001).
Asante-Appiah et al., “The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase”J. Biol. Chem. 276(28):26036-26043 (2001).
Buchanan et al., “Preparation of Heterocyclyl Phosphotyrosine Derivatives as SH-2mediated Signal Transduction Inhibitors” CAS 131: 257875.
Charbonneau and Tonks, “1002 Protein phosphatases?”Annu. Rev. Cell Biol. 8:463-493 (1992).
Chemical Abstracts, “34-Amino Acids, Peptides, and Proteins” 131(19):735 (1999).
Cho et al., “Substrate specificities of catalytic fragments of protein tyrosine phosphatases (HPTP {beta}, LAR, and CD45) toward phosphotyrosylpeptide substates and thiophosphotyrosylated peptides as inhibitors”Protein Sci. 2:977-984 (1993).
Dang et al., “Synthesis of phosphonate 3-phthalidyl esters as prodrugs for potential intracellular delivery of phosphonates”Bioorganic&Med. Chem Letters9:1505-1510 (1999).
Dechert et al., “Comparison of the specificity of bacterially espressed cytoplasmic protein-tyrosine phosphatases SHP and SH-PTP2 towards synthetic phosphopeptide substrates”Eur. J. Biochem. 231:673-681 (1995).
Desai et al., “Receptor Tyrosine Phosphatases are required for motor axon guidance in the Drosophila embryo”Cell84:599-609 (1996).
Elchebly et al., “Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene”Science283:1544 (1999).
Erion et al., “Design, synthesis, and characterization of a series of cytochrome P450 3A-activated prodrugs (HepDirect Prodrugs) useful for targeting phosph(on)ate-based drugs to the liver”J. Am. Chem. Soc. 126:5154-5163 (2004).
Erion et al., “Liver-targeted drug delivery using HepDirect prodrugs”Am. Soc. Pharm.&Exper. Ther. 312(2):554-560 (2004)D0I:10.1124/jept.104.75903.
Farquhar et al., “5'-[4-(Pivalyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: a membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP)”J. Med. Chem. 38:488-495 (1995).
Flint et al., “Multi-site phosphorylation of the protein tyrosine phosphatase, PTP1B: identification of cell cycle regulated and phorbol ester stimulated sites of phosphorylation”EMBO J. 12:1937-1946 (1993).
Freeman and Ross “3. Prodrug design for phosphatases and phosphonates”Progress in Medicinal Chemistry34:112-147 (1997).
Fukada et al., “The reciprocal role of Egr-1 and Sp family proteins in regulation of the PTPIB promoter in response to the p210 Ber-Abl oncoprotein-tyrosine kinase”J. Biol. Chem. 276:25512-19 (2001).
Galic et al., “Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP”Mol. Cell. Biol. 23:2096-2108 (2003).
Griffiths et al., 2004, CAS: 141: 343429.
Harris et al., “Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromoviny1)-2'-deoxyuridine”Antiviral Chem&Chemo. 12:293-300 (2001).
Heinonen et al., “T-cell protein tyrosine phosphatase deletion results in progressive systemic inflammatory disease”Blood103:3457-3464 (2004).
Hostetler et al., “Enhanced oral absorption and antiviral activity of 1-O-octadecyl-sn-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, in vitro”Biochem. Pharm. 53:1815-1822 (1997).
Hostetler et al., “Lipid prodrugs of phosphonacids: greatly enhanced antiviral activity of 1-O-octadecyl-sn-glycero-3-phosphonoformate in HIV-1, HSV-1 , and HCMV-infected cells, in vitro”Antiviral Research31:59-67 (1996).
Kishihara et al., “Normal B lymphocyte development but impaired T cell maturation in CD45-exon6 protein tyrosine phosphatase-deficient mice”Cell74:143-156 (1993).
Klaman et al., “Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice”Mol. Cell. Biol. 20:5479 (2000).
Knaggs et al., “A QSAR study investigating the effect of L-alanine ester variation on the anti-HIV activity of some phosphoramidate derivatives of d4T”Bioorganic&Med. Chem. Letters10:2075-2078 (2000).
LaMontagne et al., “Protein Tyrosine Phosphatase 1B antagonizes signaling by oncoprotein tyrosine kinase p210 ber-abl in vivo”Mol. Cell. Biol. 18:2965-75 (1998).
LaMontagne et al., “Protein tyrosine phosphatase PTP1B suppresses p210 ber-abl-induced transformation of Rat-1 fibroblasts and promotes differentiation of K562 cells”Proc. Natl. Acad. Sci. USA95:14094-99 (1998).
Lau et al., 2001, CAS: 135: 61438.
Leblanc et al., 2001, CAS: 135: 76988.
McGuire et al. “Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans”Diabetes40:939 (1991).
Meng et al., “Regulation of insulin signaling through reversible oxidation of the protein-tyrosine phosphatases TC45 and PTP1B”J. Biol. Chem., 279:37716 (2004).
Myerovitch et al., “Hepatic phosphotyrosine phosphatase activity and its alterations in diabetic rats”J. Clin. Invest. 84:976 (1989).
Myers et al., “P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase”Proc. Natl. Acad. Sci. USA94:9052 (1997).
Myers et al., “TYK2 and JAK2 are substrates of Protein-tyrosine Phosphatase 1B”J. Biol. Chem. 276:47771 (2001).
Nishimura et al., 2002, CAS: 137: 232854.
Perkins et al., “corkscrewencodes a putative protein tyrosine phosphatase that functions to transducer the terminal signal fro mthe receptor tyrosine kinase torso”Cell70:225-236 (1992).
Pingel and Thomas, “Evidence that the leukocyte-common antigen is required for antigen-induced T lymphocyte proliferatio

Affiliated with

Also associated with

Rating

Protein tyrosine phosphatase inhibitors and methods of use... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Protein tyrosine phosphatase inhibitors and methods of use..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Protein tyrosine phosphatase inhibitors and methods of use... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4152854